Released Nov 16, 2026, after the close
10-Q filed Nov 16, 2026, 47 days after period end · 0001477932-26-007044
Q3 2026 · 10-Q
Revenue—
Net Income$4.62M$4.62M N/M vs Q3 2025+5.1% vs Q2 2026
EPS, diluted—
Operating Income-$77,010N/M
Operating Cash Flowderived-$56,742N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net Income | $4.62M | -$46.16K |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Drugs Made In America Acquisition II Corp. · CIK 2040475 · Engraved from SEC EDGAR